Cells: from Robert Hooke to Cell Therapy - Dr Sven Kili
So we have our final speaker of the two days and we thought it would be
good to bring the whole thing together with a view from industry and we're delighted that
Dr. Sven Killy, who is heading up the cell and gene therapy for GSK, is going to give the final
session on cell therapies as medicine. So could we please welcome Sven to the podium. Thank you.
Thanks very much Chris and apologies to those of you who were expecting Patrick Vallance to come
and speak today. So I'm acutely aware that I'm the only thing standing between you and a reception
so hopefully this won't take too long but really what I'd like to do is change gears a little bit
and we've had some amazing lectures and talks today with some phenomenal information about
some very detailed science and now what I'd like to do is just kind of take a step back and think
about all this incredible science and these amazing results that we've started seeing.
Where do we go next? What do we do with this? And so what I'd like to do is use some of the
programs that my teams are developing and the therapies and really look at how those would fit
into turning these into medicines. So first of all let's have a look at the industry that we work in
and that we're living in now. So really there has been a bit of a shift in the way we look at things.
So we're now looking at using cell therapies and tissue engineering and gene therapies and these
are really becoming the new tools that we're starting to use to address diseases and conditions
and this requires not just a new way of thinking or a new way of manufacturing but a whole new shift
in the way we approach patients. Everything from the diagnosis all the way up to the questions
earlier about the payment which are going to be somewhat challenging. So it's a whole paradigm
shift in the way we use this but I think it's important to realize this is not a silver bullet.
These cell and gene therapies will not be perfect for everything and we need to be able to choose
the indications appropriately so that we can address the patient's needs. So just looking very
quickly at where the investment is and this comes from the Alliance of Regenerative Medicine. This
is their Q2 2015 report and if you go over to the left hand side here you can see the Q2 2015
financing was close to five billion dollars and that's up 129 percent from the same time next year.
So people are excited about this area. We move across to cell and gene therapies
and this has gone up 200 percent and then tissue engineering has gone up over a thousand percent
and that's pretty amazing. There are a lot of investors out there and a lot of these investors
are also patients that people are very excited about this area. Now I do accept there's a bit of
a biotech bubble going on and we've seen that recently with some of the companies that their
stock prices have gone up and down but even if you take half that, so 500 percent increase, that's
still an enormous increase in this area. So there's definitely a tidal swell moving in that direction.
So looking at it a different way, a total of 247 companies were listed and this is a report
from the end of last year looking at 466 total unique therapeutic products. So this is not just
one area. This is not just focusing on cancer or one area. This is very, very broad and 700 trials.
So you really start to get an impression that there's a heck of a lot going on.
Looking here also, how it's growing. This is just company trials. These are just companies. This is
not academic institutions and we can see the main areas that we're used to are being addressed by
cell and gene therapy. So it's the oncology, the cardiovascular, central nervous system. These are
all the areas of the greatest unmet need and people are finding solutions and ways to go about
them. It is important also to see there's a lot more preclinical work than clinical work going on
and we see that. There's going to be drop-off. There's going to be failures just as we've seen
with small molecules but the impetus is definitely there and these are going to start showing results
as we've already seen from some of the earlier lectures. And the last big heavy slide that I'm
going to show you, and this just looks at the number of gene therapy trials. So this is the
number that have been approved since 1989 and we started off 1989 with one lonely trial which didn't
go particularly well. All the way up to 2015 where we're still doing fairly well and once again,
you know, we're seeing the vast majority of these are in the phase one space. So they're very,
very early on. Then we're getting into phase two and three and so there are a few phase three
trials that are really coming to fruition now. And then you can also see the bottom right hand
slide here. Cancer is really the overwhelming emphasis on the types of therapies that are
being delivered. So very much in line with that unmet medical need. So there have been some
successes and, you know, I've not put all of them up here because there are a few that have been
successful but I've put up a few interesting ones. So Glibera everyone knows about and some of the
teeny little challenges that they've faced. I've been fortunate enough to work on three of them,
Cartasel, EpiCel and Macy, which was the first combined ATMP to get approval in Europe. Prochymal
also is doing fairly well and we heard from Mesoblast earlier and that's doing well. These are
being approved in different places around the world, not only in Europe or in the US. We're about
to see the very first cell and gene therapy product approved in Japan and that's very interesting and
we've seen Prochymal has been approved in New Zealand and Canada also. So slowly but surely these
are starting to come of age. How many of you looked at Twitter and the news feeds yesterday?
So this was the latest success story that we saw from SPARC. So SPARC announced very good results
from their phase 3 trial and this was patients that demonstrated a restoration of functional
vision and improvement in light sensitivity in their trial and this was the first randomized
control trial phase 3 of a gene therapy product. So really, really amazing and this is phenomenally
positive to see. So I think we're definitely moving in the right direction. This is a young
area but we are getting there. So in terms of GSK taking a bit of a step back we've got two
main areas that we've invested in and that we are busy growing in. The first of these is autologous
gene therapy for oncology and this is a strategic collaboration with Adapt Immune formed in 2014
and I'm not going to go into a lot of detail about that because Bengt has already spoken to you
quite broadly about some of the amazing work that they're doing. And then the group that I lead up,
we developed a strategic alliance with the TJET Institute in Milan, Italy and this was formed in
2010 and we've been doing some really interesting work with them on a number of technology spaces
which I'll go into and I'll sort of use as an example of how we are developing these types of
products. So going and looking very quickly at the Adapt Immune collaboration. So this was a
collaboration with Adapt Immune looking at TCR engineered T-cells and really looking primarily
first at testicular cancer as the first indication and I'm not going to go into any further details
about that but we're very excited about the great results that Adapt Immune has had and where the
technology is likely to head. So from a gene therapy perspective we've talked a lot about
stem cells, we've talked about TCRs, CAR-Ts but we haven't really talked about gene therapy and so
I'm going to concentrate on that for a few minutes. So as I said in 2010 we started a strategic
alliance with the TJET Institute in Milan, Italy and we partnered with them for these seven
indications that you can see here. The first three of which we've taken into clinical trials and are
currently in clinical development with us at the moment. The fourth one, beta thalassemia, also
has a clinical trial ongoing and patients are currently being treated in that. So we're very
excited about the great work that's going on and that we've been able to show. So looking at them
in slightly more detail just to give you an overview and I know you know when I started and
we started talking about these diseases you know as a lowly orthopedic surgeon I had no idea what
half of these diseases were and you know I had to run back and quickly look them up. They're way too
too complex for me. So looking very briefly ADA-SCID is the first indication and this is a
life-threatening immunodeficiency. So it's a primary immunodeficiency disorder. These children
tend to die at a very very young age and they die of overwhelming infections usually nosocomial or
opportunistic infections and the only real treatment for them currently is to have a bone
marrow transplant or receive enzyme replacement. Now they do quite well if they have a matched
donor. So if there's normally a sibling who can give them a matched bone donation they do quite
well. They have sort of in the region of a 90% survival rate which is really really good. If they
have to go for an unmatched donor that starts dipping down and it dips down and dips down until
they have to go into enzyme replacement and then things start getting a little bit dire and they
don't do very well. They can't last on enzyme replacement for very long. So at the moment you've
got a very small group of patients that actually can be addressed very well and those are the ones
that are appropriate and have a matched bone marrow donation. So Wiskott-Aldridge syndrome or
WAS as we call it is the other one and this is life-threatening and people often don't refer to
it as as fatal but these children do tend to die very very young. They often die sort of in their
20s and they suffer from a profound thrombocytopenia and so they have bruises but much worse than that
they have bleeding into their joints, they have bleeding into their submucosal spaces, they even
have strokes and then as if to add insult to injury they also get autoimmune diseases and
suffer leukemia. So this is a truly truly awful disease. The other major area that we're focused
on is MLD or metachromatic leukodystrophy and this is also a particularly nasty fatal disease.
These children often tend to start walking and standing relatively well until all of a sudden
things drop off and they have this profound motor function decrease and they go from walking to not
even being able to walk, not stand, not sit and they have a particularly nasty death. What makes
this even more difficult is bone marrow transplants don't tend to work so there are no good options
for these patients and then if that wasn't bad enough even worse than that there is no newborn
screening really currently available for these patients. So the vast majority of these patients
the family has a child where they all of a sudden they start going off and it takes them ages to get
this child diagnosed and eventually that child dies but they know what it is so that if they
have another child they are much more aware of it and they can often pick it up. So it becomes
almost a trial and error basis which is not a particularly nice way to have a family. So we
focus really on these primary immunodeficiency lysosomal storage disease and blood disorders.
We're looking also at MPS1 and probate disease and we'll be starting the clinical development
programs for those in the very near future. So for those of you that are unaware or unfamiliar with
how gene therapy works this is just a very quick overview. So first of all as you can imagine the
patients that I've already discussed and talked about these are really ill patients and they have
to be looked after in high dependency specialist units and so what happens is they go into the unit
and hematopoietic stem cells are collected and these are collected either from a bone marrow
harvest or from peripheral blood cells and that depends on the technology and the therapy that
we're using. Those stem cells are then isolated and purified and occasionally if needed also
cultured up and they're then transduced. So when they're transduced they're transduced with a
vector. We use a viral vector and this is essentially a virus that has been repurposed
to be able to carry a piece of genetic material that will address that particular disease and so
there are a variety of different vectors that are currently used and have been described and for our
first indication ADA-SCID we used a gamma retrovirus which is a relatively old virus but
tends to work very, very well. For the more recent and the later project we're now using lentivirus
which Carl just mentioned and is really currently the most popular vector that's used. Now it is
important to remember when this genetic material is inserted into these cells and these cells are
properly transduced that becomes the drug and so now we are a pharma company and we are producing
for patients for a clinical trial and very soon for treatment in the market and so these cells
as this drug product have to go through all of the assessments that a small molecule or a large
molecule would go through. So they have to go through full quality control and processing
which I'll go through in a few moments is no mean feat. As that's happening the patient undergoes
conditioning so they have a conditioning regime to dampen down their inflammatory system in order to
be able to transduce these new fresh healthy cells back into them and allow them to repopulate
and to engraft within the patient and the patient is then followed up. So that in a nutshell is what
these patients go through. So you can imagine not only is this pretty complex stuff to develop and
we've heard from the other speakers today that there's an enormous amount of science but it's
fairly complex to manufacture and also to deliver to these patients. So let's have a look at ADA
SCID just to give you a bit of a brief overview and I have to apologize that the data I'm going
to present to you on this and the other two indications is a little old but I have a very
good reason for that. We have publications that are currently in process and I'm not allowed to
reveal too much information so I have to show you slightly older information, my apologies.
So currently for this publication that we had we had 18 patients treated, we've subsequently treated
quite a few more and these are all reported within the marketing authorization submission which
went in for this indication earlier this year. All patients were alive and they still are alive
so we have 100% survival. This was at a median of seven years follow-up. I can tell you the very
first patient that was ever treated with this technology is now 15 years post-treatment and
every one of these patients is now alive. To give you an example, a matched unrelated stem cell
transplant, they have less than 70% survival rate so we're pretty happy with that. In terms of
immune reconstitution, we've also had some pretty good results. 15 of the 18 are completely free
from the need for any long-term enzyme replacement or rescue stem cell therapy. So this is a one-shot
treatment that we are giving them. Obviously they have a sustained re-engraftment and so their
immune system takes a little while, takes a few months to come back but once it's back we're
seeing phenomenal results from it. One of the outcomes that was looked at for this trial was
the severe infection rate and this dropped from 1.1 per person years to 0.043 events per person
years. Now it is important to remember these are severe infections. These are infections that the
child needs to be hospitalized for or hospitalization needs to be extended and normally on intravenous
antibiotics so they're pretty serious infections. In terms of the safety, once again I've already
said it, no deaths to date and also no leukemia. So we've heard from some of the other talks,
there have been in the history we've seen before some of these patients treated with a gamma
retrovirus particularly have shown leukemias and so we've been very sensitive to this and as you
can imagine the regulatory agencies are also pretty sensitive to the whole leukemia. So we've been
very careful to follow these patients up very carefully and in looking at insertion site
analysis there've been no insertions anywhere near proto-oncogen areas and all of the adverse
events that we're seeing are very much in line with what you would expect from a bone marrow transplant.
So moving on to Wiskott-Aldridge syndrome over here on the right, as I said these are patients
with lots of bruising, lots of bleeding and this is just following three patients. Currently we
have a much larger clinical trial and I'm very excited to say that the last patient was treated
about two or three weeks ago and I heard on Sunday his transduction and his insertional
analysis are looking very good so we're very very happy with that. The outcomes from this was
that there was a sustained expression of WAS protein within the platelets and the lymphocytes
and those platelet counts have come up dramatically and in terms of major bleeding episodes they have
come down substantially so not only statistically significant but very much clinically significant.
So we're very very happy with that. This pivotal trial is ongoing and we're currently in the phase
of following these patients up. This uses a lentiviral vector but with this once again we're
also obviously looking for any signs of leukemic changes and the last indication that we're looking
at is metachromatic leukodystrophy and really as I mentioned before, what happens is a lot of
these parents and these patients have a sibling, an older sibling who's already affected and what
we saw with the first three patients that after two years each patient had done substantially better
than their sibling and they were still able to walk or stand as compared to their sibling who
had either lost the ability to walk, stand or sit or who had actually perished. So those first three
patients we were very very happy with. There is an ongoing clinical study as I've mentioned, it's now
fully enrolled and we continue to follow it up and I'd like to just show you this. This was presented
a couple of weeks ago by one of the investigators and this is an overview of the treatment and the
outcomes for the late infantile patients and these are the first nine patients in the late infantile
group. So what you'll see, this is the gross motor function score and this is the score that's used
to look at the outcomes of these patients and if you look at the grayed out area here, that is where
you would expect normal patients to be and so these grayed out dots tend to be, these are the
normal patients with a grayed out area as being the sort of the 90th percentile of normal and so
having a look at these patients, you'll see all of them bar two have really stayed within what we
would expect for normal and normally at about two and a half, three, four years, we start seeing them
drop off and very very sadly, these little orange balls at the bottom represent untreated
patients. So these are really the comparators that have been used. So you can see from an efficacy
perspective, we're absolutely dumbstruck, it's really really amazing. So it's all great, we have
all this technology and we're able to work with clinicians who are phenomenal and are able to
treat these patients very well but so what if we need to turn this into a medicinal product that
can get out to a larger number of patients than these small controlled clinical trials. So what
do the regulators look at? So most recently, the Human Tissue Authority and the Human Tissue
Directive came out and that came out from 2004 onwards and really this is something very different
to what we see in small molecules and large molecules and this covers human tissues as they
are used for drugs. Now the Human Tissue Act covers a lot of other things, it covers keeping body
parts for anatomy demonstrations, it covers mortuary work, all sorts of other things, post-mortems
but specifically in terms of collecting tissue which we have to do, we have to harvest blood and
blood components from these patients so we're bound by the Human Tissue Act and that describes
how patients are selected, how they're consented, how the actual biopsy is taken, how it's stored,
how it's tested and how it's transported. So everything that happens up until the point where
you manipulate those cells in a meaningful way is all covered by the Human Tissue Directive and
that's something that's kind of unusual and we have to work very closely with clinicians and
hospitals to educate them around these legal requirements and then for the second part, once
those cells have been manipulated, they then become a drug and that's then covered by the
ATMP regulations which is the Advanced Therapy for Medicinal Products and that was published
at the end of 2008 and came into effect and really covers all cell therapies, all tissue
engineered products and all gene and cell therapies and what that says is that these are now seen as
pharmaceutical drugs and when you develop them, you are required to show the same
level of rigor in your development and your clinical efficacy and your follow-up and your
safety as you would for developing a small molecule, an antibiotic, a whatever and so this
has really been a ground change for a lot of companies and particularly smaller companies
trying to develop these technologies because it put in a lot more requirements for testing,
for development, for manufacturing and it's made it substantially more challenging,
particularly for smaller companies. Now I do hasten to add, in the medium to long term, it's
absolutely the best thing for patients because there were a lot of rogue companies out there
that were perhaps developing products that were maybe not quite as kosher as they should have
been and so this is a very good thing but it is challenging for small companies that don't have
the expertise and so it covers things like good manufacturing practice, good clinical practice
in development, pharmacovigilance, risk management, packaging, marketing material, everything from
beginning to end and so we're now in this new environment in which as we develop these products
and as we start putting them into patients and even before we put them into patients, we are
required by the agencies, the FDA, the EMA, the PMDA, all of these agencies to show specific levels
of criteria which is substantially more than we used to have to just show from an academic perspective.
So I think we've been able to see, go from the left hand side here, does it work? I think we know
on the gene therapies that I've shown you, yes it does work but now the big question is how do we
manufacture and supply it? Carl was talking about an N of one patient and we can. We can
manufacture in academic institutions very, very well but for very small numbers of patients but
what happens when you're getting out to indications that have larger numbers of patients? How do you
manufacture for much larger indications? So this just to give you a little bit of an overview of
how we approached some of these aspects. So this is using an example of our gamma retrovirus for
ADA-SCID and really these are some of the things that we thought about and we ended up addressing.
So up at the top left you can see originally using a master cell bank and this was a murine retrovirus
system that was being used and what we did was we moved down into developing really a working
cell bank which allowed us to have a lot more cell line stability and clonal stability and that
allowed us, instead of when developing a new batch of vectors, instead of going from the master cell
bank, you could have this quality controlled working cell bank and move from there and that's
now really sort of become the industry standard for cell therapies. In terms of culture processes,
started using adherent flasks. We also started using cell factories allow us to create much
larger volumes of cells and be able to then supply larger numbers of patients and that's scale up
far more effectively. Raw materials, this is absolutely critically important. So we went to
validated raw material providers. You'd kind of think, well, wouldn't you do that anyway?
But the price of them goes up quite substantially just because they've got that really cool looking
certificate and also these had to be TSE compliant manufacturers. So there's a lot of
stuff that has to go on over there and so what we ended up doing is optimising our batch manufacture
for these vectors so that we could treat larger numbers of patients per batch. So if you think
about a lot of autologous cell therapies, every patient was a batch. Now what we're able to do
is take the vectors and make one batch for a number of patients and what this does is it speeds
things up, it brings the cost down and it simplifies things. Then in terms of the virus
purification, we did quite a lot of work in order to purify the virus and be absolutely certain that
the viruses that were being developed were in absolutely the best state and then we did a lot
of work on looking at containing and being able to preserve and freeze these down so that they
could be used over a longer period of time and stabilise the manufacturing process. Those of you
in the audience that are working in gene therapy, you'll know that certain of these virus vectors
are somewhat challenging to manufacture and being able to manufacture them in large batches and have
them on hand can often be easier said than done. So looking at cell production, this is fairly
basic. I've gone through it. We take bone marrow, generate CD34 cells, stick the viruses, the vectors
inside with the new genetic material, bing bang boom, you've got a drug product. Easy. So what we
did was we had to kind of go back and say right, how do we do this properly? How do we do it to
satisfy this most stringent person looking at this? And so we spent a huge amount of time looking at
developing assays and we developed dozens and dozens of assays in order to be able to show a
continuous process improvement and process monitoring so that we were very comfortable
with everything from the starting product, our version of the API right at the beginning there,
being able to ensure that it's contained well, that there's no chance that it might be exposed
to any contaminants, that it's being checked at all stages. Raw material changes, as I've already
mentioned, were very, very important. Introducing wash stages so that there are no supernant and
there's no potential for any external material to find its way in. So there's an enormous amount of
work that goes on there before the quality person at the end of the line is happy to sign their name
to that product to be given to a patient. So this is an enormous area of work and there is still a
lot of work that has to be done as we learn to scale these types of cell and living therapies up
to a larger level where we can treat more and more patients at a time. And we need to continue to
learn to develop and to optimize what we're doing and how we're doing it. And so lastly,
this just gives you an overview. Currently, patients are being treated, if I can find my
pointer, here and manufacturing is happening here at a manufacturer called MolMed in Italy.
And so really, what we need to do is we need to now make sure that we're able to get these
treatments out to patients, get them out to patients all over the world. So we're currently
in the process of developing two different things, manufacturing centers in the major different
regions, so in the Americas, Europe, Middle East and the Far East, and then also optimize the shelf
life so that these patients don't have to travel too far. They can be treated in their local
specialized centers so that we are not, as a therapy provider, not creating more stress for these
young families whose lives are already turned upside down. And so we're looking at ways of
making it more efficient and better to be able to treat them more close to home.
And that's everything from me. So I hope that sort of gives you an overview of where we're going,
where the therapy area is going in terms of using cells for drugs. And just as a lasting thing,
this is Sebastian, and this is the young man who underwent the very first gene therapy
transplant. So this is 15 years down the line. Thanks very much.
Excellent. Sven, I'm going to ask the first question, because a common question that's
come up is, how much is it going to cost? So it'd be really nice if you could go through
how GSK is going to handle this, especially on these ultra rare indications. Yeah, I had a funny
feeling you were going to ask that, Chris. So this is a question that we had a meeting in Spain last
week, and this is one of the questions that came up. And it's been asked to a couple of the other
speakers also. And undeniably, these are expensive products to make. They're very complex. They're
very, very expensive. And so I'm not taking away anything that Carl and Bengt said. All I'm saying
is hopefully we'll add on to that. And so I don't want to repeat anything that they've said.
Yes, they are expensive, and they will be expensive to start with. I think where GSK comes
from is we have decided if we're going to play in this space, we're going to do it properly.
And so what we've done is we've created a cell and gene therapy group, and that group is really
focused on this. And for some stupid reason, they recruited me into Head It Up, which I still don't
quite understand. But essentially, we have the commitment to take these forward. And as you can
imagine, how many of you have heard of ADA-SCID before you came here today? It's not the most
common disease. We're probably only going to treat between 5 and 10 patients in the first year.
And maybe at the peak time of treatment, if we get 20 patients in a year, I think that'll be a lot.
So these are really small numbers. But what this allows us to do is to develop the expertise,
not only with the people in developing these products and being as efficient as possible,
but also our manufacturing. So to develop a manufacturing and a supply chain capability
to manufacture these products in greater numbers more efficiently so that we can take learnings
from ADA-SCID to MLD to WAS and to all of the other indications that are coming behind.
And so initially, we're not looking to make a big profit. That's not what we're here about.
We're about being able to make these therapies available to patients. I think the profit and
the payback will come once the larger indications come, but we're able to scale down the price per
patient. But initially, it is going to be expensive. There's just no way getting around
that. And I mean, I liked Carl's example about the computers in the beginning and about
the DNA screening. Initially, it was expensive. As we learn more about the manufacturing, as we maybe
go to more automated manufacturing, that's when I think we can bring the price down. But that's
going to take some time. And the cost, I mean, we've discussed before, but I mean, a lot of it is
things like being able to provide accommodation for the families while they're there. I mean,
Yeah. So currently, when patients go to Italy for the clinical trial to be treated, they stay
in Italy, in Milan, for between four and six months. And so they need to be put up.
They need to have interpreters. They need to live in an apartment that doesn't have carpets
so that it can be properly cleaned because when they undergo their transduction,
their immune system is really not very good. And so they need to be looked after much more
carefully. They need to have taxis to and from the hospital. They need to buy food.
The family comes over with them. And very often, it's not just sort of the mother that comes over
and the father that stays behind. Often, it's an extended family comes over. So the costs rise
tremendously. And so we're working very hard with the Telethon Institute to understand how to
support these patients in order to be able to receive these products. And so if you look at
the costs of treating these patients, I'd describe it almost in three buckets. One is
what it costs to manufacture the product. What does that product cost? The other cost is then
the hospital costs to pay the clinicians, pay the nursing staff, all of the drugs.
And then the last one is what happens to those patients living? And that's kind of that third
cost. And so we're very focused on being able to ensure that patients are able to receive the
treatment and no one is not able to receive because of their inability to pay.
So the question is working up towards larger indications. What indications are we talking
about? Yes. So at this stage, we have a number of larger indications that we are busy exploring.
Because some of them are in confidential discussions, I'm sorry, I'm not able to talk
about them. But I think where we'd be looking to go is we've already got the oncology collaboration.
And so some of those indications have the potential to become quite large. You saw things
like beta thalassemia up there. I think once we start really understanding what we can do and what
the technology is and bringing in certain of the gene editing technologies, I think then things
really start expanding. And so my team at the moment is really kind of looking at the technology
landscape and saying, where do we go next? But I can't give you specific indications at this stage,
I'm sorry. Any other questions for Sven? Great. Can we thank Sven for a super talk?
Thank you very much. Thanks, Sven. Very nice. Thank you. Thank you.

